People
The People
Governance grade is C–: founder-controlled via dual-class voting, an unresolved trail of related-party/SEC-era allegations, recent large insider sales into a 52% drawdown, and the independent board Chair stepping down — partially offset by a credible biotech-savvy audit chair and modest cash salaries.
Governance Grade: C-.
Skin-in-the-Game (1–10)
Directors+Officers Voting %
Founders + Co-founders Voting %
Read this first. Ginkgo's 2021 Scorpion Capital report alleged 72% of 2020 revenue came from related-party entities Ginkgo created or funded. A DOJ informal inquiry followed; an internal Milbank-led review concluded the allegations were "unfounded"; the company nonetheless paid $2.75M in 2025 to settle derivative shareholder claims. The shares are down roughly 97% from the 2021 peak. Every governance call here lives in that shadow.
1. The People Running This Company
The operating company is run by two co-founders who have controlled it since 2008 — Jason Kelly (CEO) and Reshma Shetty (President) — alongside a CFO who only stepped up in May 2025 after his predecessor resigned. A third co-founder, Bartholomew Canton, is Dr. Shetty's spouse and the company's largest individual beneficial owner.
Jason Kelly (CEO, 18-yr tenure). MIT PhD in biological engineering, co-founded Ginkgo in 2008, led the $15B SPAC merger with Harry Sloan's Soaring Eagle in 2021. Has navigated the company through the 2021 short-seller crisis, the DOJ inquiry, a 35% workforce reduction in 2024, and the post-SPAC collapse. Capability is not in dispute; the open question is whether the storytelling discipline that worked pre-IPO carries to an audited public company.
Reshma Shetty (President & Founder). Also MIT PhD, co-founder since 2008, served as COO 2008–2025. Married to co-founder Bartholomew Canton — material because Canton is a separately reported 5%+ owner whose holdings drive Dr. Shetty's 29.2% voting power.
Steven Coen (CFO since 30 May 2025). Promoted from Chief Accounting Officer after Mark Dmytruk's abrupt resignation on 6 June 2025. CFO transitions executed during a regulatory hangover and steep stock decline are a credit-watch item; Coen is the company's third finance lead in the post-SPAC era.
Succession risk and key-person concentration. No identified COO since Dr. Shetty vacated the role in 2025. The CEO and President are spouses of, or co-founded the company with, the largest individual shareholders. A bench beyond the founder circle is not visible.
2. What They Get Paid
Cash salary is unusually low ($250K for both founders, near the median Boston biotech manager). The real number is equity, and FY2025 saw a step-change: Kelly's stock awards jumped from $0 in FY2023 to $5.45M in FY2025 — a one-time mega-grant that more than quintupled his reported total comp in a year when revenue stagnated and the stock fell.
Is the pay sensible? Cash salary is defensible — $250K is well below peers and signals founder commitment. The 2025 stock grants, however, were sized to compensate for years of token equity awards (FY2023 totals were $262K — essentially nothing) and were issued at a depressed stock price, which boosts the share count delivered to founders. CEO/median-employee ratio is 32x ($5.71M vs $176K median), low for a US large-cap but high for a company missing breakeven targets and laying off 35% of staff in 2024. Critically, the equity vested in 2025 is part of the same year the founders began materially selling stock (see section 3) — pay-for-performance is undermined when the equity becomes a liquidity channel rather than a long-term alignment tool.
3. Are They Aligned?
The headline alignment number — 44.2% directors+officers voting power — overstates economic alignment. It is delivered by the dual-class structure: Class B shares carry 10 votes each, so founders' modest cash investments translate into outsized control. Including co-founder Austin Che (14.3% voting, not on board), the founder bloc commands roughly 58% of votes on under 20% of economics.
Insider activity is the red flag
In early April 2026 — with the stock down 52% over six months and a Sell rating from BTIG at a $5 price target — the founder circle executed a coordinated, multi-day cluster of Form 4 sales at $6.40–$6.93 per share.
The April 2026 selling cluster is an alignment concern even at the corrected dollar scale. The founder team's open-market sales total roughly $2.4M (Kelly ~$1.37M plus the Shetty/Canton household ~$978K, since spouses cross-report the same shares as direct/indirect on each filer's Form 4), with the CFO adding ~$216K. Founders sold at $6.40–$6.93 — near multi-year lows, with the stock already down 52% over six months. Discretionary insider selling at depressed prices, by founders with low cash salaries who control the equity grant calendar, is the inverse of skin-in-the-game behavior.
Dilution and capital allocation
The 2025 equity grants ($5.45M to Kelly, $3.22M to Shetty, $0.89M to Coen — all stock, no options) were granted just before founders monetized their existing positions. Diluted share count has expanded materially since the 2021 SPAC, while $840M of post-SPAC cash has funded heavy R&D losses without producing a sustained revenue inflection. The company is targeting adjusted EBITDA breakeven by end-2026 but the interim path has involved a ~35% headcount cut (≥400 employees in 2024).
Related-party history is not closed
The DOJ inquiry status remains publicly undisclosed five years later. A $2.75M settlement is modest in dollar terms but is the second concrete admission that the related-party fact pattern was strong enough to extract a payment — first the class action settlement, now the derivative settlement.
Skin-in-the-game scorecard
Composite Skin-in-the-Game Score
Overall: 5/10. Founder ownership is real and discipline on cash salary is genuine — but the April 2026 insider-selling cluster, the timing of the FY2025 mega-grants, and the unresolved related-party history collectively neutralize the structural ownership advantage.
4. Board Quality
After the 2025 Annual Meeting, the Board shrinks from 7 to 6 directors as independent Chair Shyam Sankar (Palantir CTO) does not stand for re-election. The post-AGM structure: 2 inside founders + 4 independents. Independence on paper is fine; functional independence is thinner than the percentages suggest.
Board Scorecard (0 = absent, 10 = strong)
What the matrix tells you. Christian Henry is the genuine asset — Pacific Biosciences CEO, ex-Illumina CFO, Audit Chair. He has the resume to challenge management on revenue recognition, which is precisely the historical pressure point. Sri Kosuri brings technical synbio depth but runs a competing private synbio drug discovery company (Octant) — a functional-conflict to monitor on strategy and IP matters. Harry Sloan brought Ginkgo public via Soaring Eagle SPAC; technically independent under NYSE rules, but he was the dealmaker on the original $15B valuation that subsequently fell 97%.
Two structural weaknesses. (1) The Compensation Committee Chair is changing hands twice in a year — Sankar to Fubini, a 2-year board member with no biotech operating background — at the moment the founder pay package became material. (2) After Sankar's departure, the Board has only two members with deep biotech operating chops (Henry, Kosuri), and Kosuri carries a conflict. The committee work that should police related-party transactions and equity grants is thinner than it looks.
Independent Directors (post-AGM)
Independent %
Women on Board (post-AGM)
Board Meetings in 2025
Note: Dr. Kathy Hopinkah Hannan and Myrtle Potter both rolled off at the 2025 AGM; Dr. Shetty is the only woman on the post-AGM board. Director attendance disclosure is the standard ">75% threshold" — no specific attendance is broken out.
5. The Verdict
Final Governance Grade: C-. Analyst signal: Sell-rated by BTIG.
The strongest positives. Real founder ownership backed by a low-cash, equity-heavy compensation philosophy. A genuinely qualified Audit Chair (Henry) covering the exact area — revenue recognition — that has caused trouble before. No bank debt and $840M of cash, so the board is not under near-term solvency duress.
The real concerns.
- Dual-class voting plus a married co-founder couple controlling ~29% of votes makes any future hostile remedy effectively impossible without founder consent.
- April 2026 insider selling cluster of ~$2.4M by the founder team (Kelly $1.37M plus Shetty/Canton household $978K, with spouses cross-reporting the same shares) plus ~$216K by CFO Coen, all at multi-year-low prices, is the most unfriendly signal in this file — and it was preceded by FY2025 equity grants that look retrospectively timed.
- CFO turnover mid-2025 and the independent Chair leaving in 2026 strip out two of the senior governance check-and-balance roles in the same 12-month window.
- Related-party history is not closed: DOJ inquiry status unstated since 2021; two settlements paid; the same revenue-recognition pressure point that triggered Scorpion's report still defines the audit risk today.
- Sri Kosuri chairs Nominating & Corp Gov-track work while running Octant, a private synbio competitor — at minimum a recusal item.
What would change the grade.
Upgrade trigger: Open-market insider buying by Kelly or Shetty at any price for two consecutive quarters; an unequivocal close-out disclosure on the DOJ inquiry; appointment of an independent Chair with biotech-CFO or audit-committee pedigree; a multi-year clawback policy with teeth.
Downgrade trigger: Any new SEC or DOJ action; further insider selling at the current price range; a related-party transaction disclosed in 2026 financials; Christian Henry departing the Audit Committee without a comparably credentialed replacement.